Browse the evidence

Metabolic dysfunction associated steatohepatitis (MASH) is a leading cause of chronic liver disease worldwide.

Healthcare providers should recognize MASH as a significant health concern.

MASLD presents extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, and chronic kidney disease.

Clinicians should consider the broader health implications of MASLD beyond liver health.

Obesity, sarcopenia, and heart failure with preserved ejection fraction (HFpEF) are interconnected through the adipokine axis.

Understanding the link between these conditions can guide treatment strategies.

Fecal transplant may have a preventive role in diabetes progression.

Consider the potential of fecal transplants in diabetes prevention strategies.

Increased consumption of simple sugars and fats is directly related to changes in the composition and functions of gut microbiota.

Dietary recommendations should consider the impact of sugar and fat on gut health.

Statistical methods can separate variability into participant-by-training interaction and within-participant variance.

Using these statistical methods can enhance the accuracy of individual training assessments.

Patients who have undergone significant weight loss are at increased risk of thromboembolic events, particularly after body contouring procedures.

Practitioners should monitor thromboembolic risk in post-weight-loss patients undergoing surgery.

Factors such as autonomic dysfunction, left atrial stretch, inflammation, and hormonal imbalances contribute to AF in obese individuals.

Understanding these factors can help in developing targeted interventions for AF in obesity.

MPDA@TZP increased the retention time of TZP in the iWAT of mice and had a more dramatic effect on weight loss and improvement in plasma lipid profiles compared to TZP alone in DIO mice.

Encapsulating tirzepatide may enhance its effectiveness for weight loss in specific adipose tissues.

Endoluminal metabolic and bariatric therapy may be an appealing option for patients ineligible for or averse to bariatric surgery.

Practitioners should consider these therapies for patients who cannot or do not want to undergo traditional surgery.

Future studies investigating the long-term effects of chronic high protein intake on bone tissue health are warranted.

Practitioners should consider the need for ongoing research into the long-term impacts of high protein diets on bone health.

Mitochondrial dysfunction plays a pivotal role in the onset and progression of diabetes.

Understanding mitochondrial dysfunction can guide therapeutic strategies for diabetes management.

Innovative therapeutic strategies are needed to address mitochondrial dysfunction in diabetes.

Practitioners should consider new therapies targeting mitochondrial function in diabetes care.

Changes in vastus lateralis muscle thickness did not statistically differ between training programs with different proximities to failure.

Practitioners may consider that varying proximity to failure does not significantly impact muscle thickness gains in trained individuals.

No significant differences were observed in relative volume between the 4-6 RPE and 7-9 RPE groups.

Practitioners can expect similar training volumes to yield comparable results in muscle adaptations.

The between-group effect sizes for changes in MT were trivial to small.

The differences in muscle hypertrophy between training intensities may not be clinically significant.

The findings regarding PM muscle hypertrophy between the different RPE groups are statistically inconclusive.

Further research is needed to clarify the effects of training intensity on muscle hypertrophy.

Grip strength declined by 38% following semaglutide treatment.

Monitoring grip strength may be important in patients receiving GLP-1RA therapy to assess muscle function.

Key therapeutic areas include innovative approaches for monogenic disorders, incretin mimetics, dual receptor agonists, microbiome analysis, and improved behavioural interventions.

Practitioners should consider these therapeutic areas for advancing treatment options.

The etiology of obesity is multifactorial, and long-term weight maintenance remains challenging.

Interventions for obesity must consider the multifactorial nature of the condition.

Adverse effects of dual agonists are largely gastrointestinal and manageable.

Healthcare providers should inform patients about the manageable gastrointestinal side effects of dual agonists.

All exercise groups (WB-EMS, Pilates, Yoga) significantly reduced muscle mass during diet-induced weight loss compared to the control group.

Incorporating exercise like WB-EMS, Pilates, or Yoga can help mitigate muscle loss during weight loss diets.

The activation of GLP-1R by semaglutide or THDBH120 improved lipid metabolism.

GLP-1R activation could be targeted for improving lipid metabolism in obese patients.

The activation of GIPR by LAGIPRA or THDBH120 alleviated inflammation.

GIPR activation may be beneficial for reducing inflammation in obesity-related conditions.